Here, we have investigated for the first time the preclinical activity in a brain tumor of a novel, orally bioavailable PI3Kα inhibitor, MEN1611, finding a strong anti-cancer effectiveness against Ptch1+/−/Tis21KO MBs. Here, PTCH1 is linked to brain neoplasm.